collaboration! Qixin Technology and the industry join hands to create a regenerative medical ecological chain to promote innovation in the emerging biotech and pharmaceutical industry
Qixin Technology participated in the Taiwan Medical Technology Exhibition and held a regenerative medicine seminar concurrently
The 7th Taiwan Medical Technology Exhibition 2023 will be held on 11/30. The exhibition will last for four days from 11/30 to 12/3. It will consist of three main axes, nine key areas, and two major themes: smart medicine, precision medicine, and all-age health. The special exhibition consists of a total of 2,500 booths, gathering professional companies and innovative technologies from Taiwan and abroad, demonstrating Taiwan’s unique soft power of medical technology and hard power of cutting-edge technology, and jointly promoting the new industrial pattern of information and communication technology, biomedical industry, etc. , and has become the largest platform for global supply chain cooperation and international business cooperation.
Qixin Technology has been deeply involved in the local market for more than 40 years. From Taiwan’s first GMP-certified culture medium manufacturing factory to now, its own brand CMP has more than 600 kinds of finished culture media and diagnostic reagent products, and has cooperated with 33 international new manufacturers. Brand cooperation, working together to meet customers’ diverse product needs, has become a leading brand in the field of microbial testing. This year, it was recognized by the Biotaiwan Outstanding Biotechnology Industry Gold Award, Taiwan’s highest honor in biotechnology, and the Entrepreneurship Model Award, and participated in this year’s Taiwan Medical Technology Exhibition. At the same time, a seminar and media conference on “International Trends and Innovation Ecosystem of Regenerative Medicine” were held to demonstrate its response to the market demand for cell therapy.
The development of international trends in regenerative medicine can be expected to lead to new technologies and join forces with the industry to provide international standard services.
According to GlobalData statistics, there are more than 1,000 cell and gene therapies approved for marketing worldwide, and the number of approvals has grown steadily since 2021. Looking at the regions where all approved projects are located, North America has the highest proportion of 651 projects, followed by the Asia-Pacific region with 453 projects and Europe with 230 projects. In recent years, in addition to the approval of many gene therapies for rare diseases, many innovative immunotherapy methods have emerged. The future direction of gene and cell therapy will likely be towards quantified production, optimized policy and regulatory environment, and the scope of treatment will include more diseases. Etc., there will also be stricter standards for process control to ensure quality.
In view of this, in the “International Trends in Regenerative Medicine and Innovation Ecological Chain” seminar and media conference, Qixin Technology invited Dr. Shen Jianing of Taiwan Academia Sinica, Professor Shen Yaoan of Peking University Medical University, and Dr. Cai Jiaqe, founder of CellTech Innovation Accelerator, to “Cancer stem cell screening technology platform and cell therapy development”, “Taiwan’s new regenerative medicine industry ecological chain”, “Current status of the international cell therapy industry and Taiwan’s development opportunities” and other topics, jointly discuss the development of the field of cell and gene therapy, hoping to promote Exchange and innovation among biotechnology and medical industries.
In the future development plan of Qixin Technology, we have integrated various service capabilities such as academic research, R&D, production, distribution agency and funding, and invested in the construction of PIC/S GMP dedicated to the biomedical supply chain in the Zhubei Biomedical Park. The Zhubei factory will be used to prepare for mass production of cell culture media products and provide commissioned inspection and CDMO services. It plans to start testing services related to cell therapy preparations in 2024 and provide Qixin’s own brand products from 2025. Cell therapy peripheral products will further expand into the international market with the advancement of development in the future to achieve a comprehensive layout.
